Analysis
Warhound came out of stealth Thursday backed by $200 million in funding from investors including Sequoia, 8VC and In-Q-Tel -- the venture firm funded by the CIA and other U.S. intelligence agencies -- at a reported $1.2 billion valuation, according to TechCrunch. The company plans to genetically engineer working dogs for the U.S. military, law enforcement and emergency response teams, addressing what it describes as a shortage of trained service dogs.
Betting on dogs that don't exist yet
Warhound is the latest venture from Ben Lamm, best known for Colossal Biosciences' de-extinction work on the dodo, the woolly mammoth and the dire wolf. Colossal holds equity in Warhound and licenses its gene-editing platform to the new company; Viagen, another Colossal-owned business, will handle cloning. Palmer Luckey, Anduril's founder, is a partner in the venture but holds no equity, per Lamm -- Anduril's role is supplying hardware and software, including protective vests and goggles, that the dogs would eventually wear.
“Colossal holds equity in Warhound and licenses its gene-editing platform to the new company; Viagen, another Colossal-owned business, will handle cloning.”
The dogs themselves would be bred from Belgian Malinois and German Shepherd cell lines, edited for performance and health traits before birth. Lamm's team expects the first litters early next year, with operational service roughly two years away. That timeline matters: the $1.2 billion valuation is pricing a product that does not yet exist, running on the same gene-editing infrastructure Colossal built to resurrect extinct species rather than breed better military dogs.
In-Q-Tel's participation is the detail worth watching closest. The firm doesn't typically write checks on sentiment -- it funds technology the intelligence community believes it will eventually need, and its presence here suggests gene-edited working animals are being evaluated as a real capability gap, not a novelty. Pulse has tracked Sequoia across several of this week's other deals, and 8VC's involvement extends both funds' existing defense-tech exposure (both are Anduril investors) into a biotech-adjacent category neither has previously bet on at this size.
The risk is straightforward: breeding programs, FDA-adjacent biologic review, and military procurement cycles all move slower than software timelines, and Lamm's own Colossal ventures have a history of generating headlines well ahead of shipped product. Whether Warhound's valuation holds will depend on whether "early next year" survives contact with an actual breeding program.
